lipid nanoparticle sirna treatment ebola-virus-makona-infected nonhuman primates 
current outbreak ebola virus west africa unprecedented causing cases fatalities previous outbreaks combined yet controlled several post-exposure interventions employed compassionate use treat patients repatriated europe united states however vivo efficacy interventions new outbreak strain ebola virus unknown show lipid-nanoparticle-encapsulated short interfering rnas sirnas rapidly adapted target makona outbreak strain ebola virus able protect % rhesus monkeys lethal challenge treatment initiated days exposure animals viraemic clinically ill although infected animals showed evidence advanced disease including abnormal haematology blood chemistry coagulopathy sirna-treated animals milder clinical features fully recovered untreated control animals succumbed disease results represent first knowledge successful demonstration therapeutic anti-ebola virus efficacy new outbreak strain nonhuman primates highlight rapid development lipid-nanoparticle-delivered sirna countermeasure highly lethal human disease 
